Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07644910 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nudging Preventive Screening Via Message Framing and Bundling

StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 17, 2026 (before its estimated September 8, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria revisedv3
  2. Eligibility criteria shortened, about 15 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Chile
45 trials monitored
See 2 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Colorectal Cancer
3,394 trials monitored
See 159 trials at risk
and 2 more diseases
This study is a randomized controlled field experiment embedded in the medical institution Early Diagnosis Program in Chile. Participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned across a 3 × 3 factorial design: three message framing conditions (Basic, Risk/Importance, Peace of Mind) crossed with three exam-type conditions (cancer screening only, chronic disease test only, or both exams). Participants with only a cancer screening pending will be assigned to the 3 framing conditions and be encouraged to get the cancer screening. In both cases, participants are assigned to each experimental arm at twice the rate of an additional arm receiving the standard message currently used by the medical institution. This standard-message arm is included for operational purposes, is not part of the pre-specified analyses, and is thus not described in the "Arms and Intervention" section (or counted for "number of arms").
Trial Details
NCT Number NCT07644910
Lead Sponsor University of Chile
Conditions
(from sponsor)		 Breast Neoplasms, Uterine Cervical Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms, Diabetes Mellitus, Dyslipidemias
Related terms Breast Neoplasms, Colorectal Neoplasms, Diabetes Mellitus, Dyslipidemias, Prostatic Neoplasms, Uterine Cervical Neoplasms
Enrollment 235,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov